ReviewDrugs2018
Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A.
Review in Drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Bispecific Antibodies: From Research to Clinical Application.Frontiers in immunology · 2021Pooled it
- A Multifactorial Case of Acquired Hemophilia A.Cureus · 2026Article
- [Post-traumatic acquired hemophilia A: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Anesthetic considerations for joint replacement surgery in hemophilic arthropathy: a comprehensive review.Anesthesia and pain medicine · 2024Review
- The unique properties of IgG4 and its roles in health and disease.Nature reviews. Immunology · 2023Review
- Acquired haemophilia as a complicating factor in treatment of non-muscle invasive bladder cancer: A case report.World journal of clinical cases · 2023Article
- Management of acquired haemophilia A in severe Covid-19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis.British journal of clinical pharmacology · 2023Article
- Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study.Blood advances · 2023Article
- Acquired hemophilia associated with vedolizumab in a patient with hemorrhagic rectocolitis.Blood science (Baltimore, Md.) · 2023Article
- Acquired hemophilia A (AHA): underreported, underdiagnosed, undertreated medical condition.The Egyptian journal of internal medicine · 2022Review
- Article
- [Chinese guidelines on the diagnosis and treatment of acquired hemophilia A (2021)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Management of acquired hemophilia A: results from the Spanish registry.Blood advances · 2021Article
- Principles of care for acquired hemophilia.European journal of haematology · 2021Review
- [How I diagnose and treat acquired hemophilia A].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Anticoagulation for Stroke Prevention after Restoration of Haemostasis with Emicizumab in Acquired Haemophilia A.European journal of case reports in internal medicine · 2021Article
- Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.Thrombosis and haemostasis · 2020Review
- Article
- Utilization of Emicizumab in Acquired Factor VIII Deficiency.The American journal of case reports · 2020Article
- An Interesting Case of Acquired Hemophilia A in an Elderly Patient Presenting with Hematuria.Cureus · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies inhibiting the function of coagulation factor VIII. It is characterized by spontaneous bleeding in patients with no previous family or personal history of bleeding. Although several large registries have collected clinical data on AHA, limited information is available on the optimal management of AHA because controlled clinical trials are lacking. AHA can easily be diagnosed if the problem (prolonged activated partial thromboplastin time in a bleeding patient) is recognized. After the effects of anticoagulants are excluded, low factor VIII activity and the detection of circulating inhibitors confirms the diagnosis. However, lack of familiarity with this rare condition may delay diagnosis and adequate therapy. Treatment of AHA is based on measures for prompt hemostatic control to stop (and prevent) bleeding, immunosuppression to eradicate the autoantibodies, and supportive care for the adverse effects of that treatment and patients' often complex comorbidities. This article gives a comprehensive overview of the current knowledge about the pathophysiology, diagnosis, and treatment of AHA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.